Fig. 5

PDO and PDX models confirm the synergistic effects of Lenvatinib and Avapritinib on HCC. (A) Comparative histopathological features between HCC Patient-Derived Organoids (PDOs) and their corresponding original tumors, with representative H&E staining and IHC images for GPC3 and PDGFRA in both HCC PDOs and original tumors. (B) Live/dead cell imaging of PDOs following treatment with lenvatinib, avapritinib, or a combination of both, as indicated. (C) Quantitative analysis of cell viability in PDO models after treatment with lenvatinib and avapritinib. (D) Representative H&E staining and IHC images for PDGFRA and Ki67 in the Patient-Derived Xenograft (PDX) tumor model, with the right panel displaying the H-Score for PDGFRA in four PDX models. (E–G) PDX model mice were treated with lenvatinib, avapritinib, or a combination of both. Representative tumor growth curves (E) for xenograft tumors (F) and tumor weight (G) of PDX mice from the indicated treatment groups are presented. (H) Representative H&E staining and IHC images for PDGFRA and Ki67 in the PDX model are shown